Redmile Group

Redmile Group is a prominent San Francisco-based investment firm established in 2007 by Jeremy Green, known for its exclusive focus on the global healthcare sector. Operating as a crossover fund, Redmile deploys capital across various stages, encompassing venture, growth equity, and public market investments. This comprehensive strategy allows the firm to support healthcare companies throughout their lifecycle, from promising private ventures to established publicly traded entities. Their deep specialization provides them with a nuanced understanding of the complex and rapidly evolving healthcare landscape, enabling them to identify and back innovative companies in biotechnology, pharmaceuticals, medical devices, and healthcare services.

With substantial assets under management, reportedly around $10 billion, Redmile Group is a significant player in healthcare finance. The firm is recognized for its long-term conviction in its investments, often taking substantial positions in companies they believe will drive future medical advancements. Their investment approach is characterized by rigorous due diligence and a commitment to partnering with management teams to accelerate growth and achieve strategic milestones. This often translates into participation in large, late-stage private funding rounds, where they can provide significant capital to scale operations or advance clinical programs.

While precise "first check" sizes for a crossover fund like Redmile are not always publicly disclosed in the same manner as traditional venture capital firms, their participation in multi-million and even multi-hundred-million dollar funding rounds suggests a substantial deployment of capital. For private growth equity investments, Redmile typically invests sums ranging from approximately $25 million for significant minority stakes to over $150 million for leading or co-leading major financing rounds. Their ability to invest across both private and public markets provides portfolio companies with a stable and long-term capital partner, capable of supporting them through IPOs and beyond.